In vivo dendritic cell reprogramming for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Cancer immunotherapy faces challenges due to poor antigen presentation and immune cell exclusion within the tumor microenvironment.
• Current immunotherapies have limited success in achieving widespread, long-term patient survival.

Purpose of the Study:

• To develop an in vivo method for reprogramming tumor cells into antigen-presenting dendritic cells.
• To investigate the potential of in vivo immune cell reprogramming to enhance anti-cancer immunity and overcome treatment resistance.

Main Methods:

• Adenoviral delivery of transcription factors (PU.1, IRF8, BATF3) to reprogram tumor cells in vivo.
• Assessment of reprogrammed cells' ability to present antigens and function as dendritic cells.
• Evaluation of tumor microenvironment remodeling, T cell recruitment, tumor regression, and systemic immunity in mouse melanoma models.
• Testing reprogramming efficacy in human tumor spheroids and xenografts.

Main Results:

• Reprogrammed tumor cells effectively presented antigens, mimicking type 1 conventional dendritic cells.
• In vivo reprogramming remodeled the tumor microenvironment, attracting and expanding cytotoxic T cells.
• Significant tumor regressions and long-term systemic immunity were observed in mouse melanoma models.
• Reprogramming proceeded effectively in human tumor models, independent of immunosuppressive factors.

Conclusions:

• In vivo reprogramming of tumor cells into immunogenic dendritic-like cells is a feasible strategy for cancer immunotherapy.
• This approach can overcome common immunotherapy limitations, such as poor antigen presentation and immunosuppression.
• The findings support the advancement of in vivo immune cell reprogramming for human clinical trials in cancer treatment.